Intravenous Ketamine or Esketamine in Adolescents With Major Depressive Disorder: A Systematic Review
Alpha Psychiatry · 27.08.2026 · 27 (5)
DOI: 10.31083/ap48866 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Alpha Psychiatry, online erschienen am 27.08.2026. Verfasst von Zhen-Juan Qin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, 545005 Liuzhou, Guangxi, China. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Medical and Health and Appropriate Technology Development and Promotion Application Project, Guangzhou Health Technology Project, Youth S&T Talent Support Programme of Guangdong Provincial Association for Science and Technology.
Abstract (Originalsprache)
Background
The therapeutic efficacy and safety of intravenous ketamine or esketamine in adolescents with major depressive disorder (MDD) remain insufficiently defined. This systematic review of randomized controlled trials (RCTs) aimed to evaluate the efficacy, safety, and tolerability of intravenous ketamine or esketamine in this population.
Methods
A comprehensive search of four international databases (PubMed, EMBASE, PsycINFO, and the Cochrane Library) was conducted to identify RCTs comparing intravenous ketamine or esketamine with intravenous midazolam in adolescents with MDD.
Results
Three RCTs involving a total of 134 adolescents with MDD were included. Two trials assessed the antidepressant effects of intravenous ketamine compared with intravenous midazolam, with inconsistent findings. No significant advantage of intravenous ketamine over intravenous midazolam was observed in reducing anxiety symptoms (1 RCT). One trial compared intravenous esketamine with intravenous midazolam and evaluated antidepressant, anti-suicidal, and neurocognitive outcomes, demonstrating the superiority of intravenous esketamine. Both intravenous ketamine and intravenous esketamine were associated with significantly higher rates of dissociative symptoms (1 RCT each), and intravenous esketamine was also linked to a higher incidence of psychopathological symptoms (1 RCT). Systematic reporting of adverse events was provided in only one of the three included RCTs.
Conclusions
Given the limited number of studies, small sample sizes, and methodological heterogeneity of the available RCTs, the current evidence base remains preliminary and insufficient to support definitive conclusions regarding the efficacy and safety of intravenous ketamine/esketamine in adolescents with MDD. These findings highlight the need for further adequately powered RCTs to establish robust and clinically meaningful evidence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, The Brain Hospital of Guangxi Zhuang Autonomous Region, 545005 Liuzhou, Guangxi, China.
- School of Clinical Medicine, School of Graduate Studies, Youjiang Medical University for Nationalities, 533000 Baise, Guangxi, China.
- Department of Psychiatry, The Affiliated Brain Hospital, Guangzhou Medical University, 510370 Guangzhou, Guangdong, China.
- Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University, 510260 Guangzhou, Guangdong, China.
- Department of Medical Administration, Liuzhou Health Commission, 545001 Liuzhou, Guangxi, China.
ORCID-Profile: Zhen-Juan Qin, Xiao-Ming Li, Jia-Bao Li, Zhi Li, Xin Wei, Hui-Lin Hu, Yu-Jiao Chen, Su-Rong Xu, Zhi-Yuan Xie, Xin-Hu Yang, Wen-Juan Dai, Yu-Hua Wei
Förderung
- Guangxi Medical and Health and Appropriate Technology Development and Promotion Application Project
- Guangzhou Health Technology Project
- Youth S&T Talent Support Programme of Guangdong Provincial Association for Science and Technology
- Guangxi Zhuang Autonomous Region Health Commission Self-Funded Research Project Contract Number
- Open Foundation Program of the Health Emergency Skills Training Center of Guangxi
- Research Project on Mental Health Work in Primary and Secondary Schools
Zitieren
APA
Qin, Z. J., Li, X. M., Li, J. B., Li, Z., Wei, X., Hu, H. L., Chen, Y. J., Xu, S. R., Xie, Z. Y., Yang, X. H., Dai, W. J., & Wei, Y. H. (2026). Intravenous Ketamine or Esketamine in Adolescents With Major Depressive Disorder: A Systematic Review. Alpha Psychiatry, 27(5). https://doi.org/10.31083/ap48866
Vancouver
Qin ZJ, Li XM, Li JB, Li Z, Wei X, Hu HL, et al. Intravenous Ketamine or Esketamine in Adolescents With Major Depressive Disorder: A Systematic Review. Alpha Psychiatry. 2026;27(5). doi:10.31083/ap48866
BibTeX
@article{Qin2026,
author = {Qin, Zhen-Juan and Li, Xiao-Ming and Li, Jia-Bao and Li, Zhi and Wei, Xin and Hu, Hui-Lin and Chen, Yu-Jiao and Xu, Su-Rong and Xie, Zhi-Yuan and Yang, Xin-Hu and Dai, Wen-Juan and Wei, Yu-Hua},
title = {Intravenous Ketamine or Esketamine in Adolescents With Major Depressive Disorder: A Systematic Review},
journal = {Alpha Psychiatry},
year = {2026},
volume = {27},
number = {5},
doi = {10.31083/ap48866}
}
EUVIMED